{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:57:01Z","timestamp":1791338221376,"version":"4.3.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C47608\/A29957"],"award-info":[{"award-number":["C47608\/A29957"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022283","name":"Creative Research Institute, Hokkaido University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222880\/Z\/21\/Z"],"award-info":[{"award-number":["222880\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100281","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:51:59Z","timestamp":1786445519000},"page":"100281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["IMiD\/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-0937","authenticated-orcid":false,"given":"Sarah A.","family":"Bird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3197-4855","authenticated-orcid":false,"given":"Marco P.","family":"Licciardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0096-8032","authenticated-orcid":false,"given":"Ananya","family":"Sukhtankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-1657","authenticated-orcid":false,"given":"Fernando J.","family":"Sialana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Ramagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakinthi","family":"Chrisochoidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-214X","authenticated-orcid":false,"given":"Yigen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-6254","authenticated-orcid":false,"given":"Brian","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3677-4804","authenticated-orcid":false,"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Bouguenina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7358-8851","authenticated-orcid":false,"given":"Hector","family":"Keun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-0028","authenticated-orcid":false,"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bneo.2026.100281_bib1","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.941742","article-title":"Lenalidomide induces degradation of IKZF1 and IKZF3","volume":"3","author":"Kronke","year":"2014","journal-title":"Oncoimmunology"},{"issue":"6168","key":"10.1016\/j.bneo.2026.100281_bib2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"7201","key":"10.1016\/j.bneo.2026.100281_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bneo.2026.100281_bib4","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem"},{"issue":"6619","key":"10.1016\/j.bneo.2026.100281_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bneo.2026.100281_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bneo.2026.100281_bib7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.2020010452","article-title":"Cereblon enhancer methylation and IMiD resistance in multiple myeloma","volume":"138","author":"Haertle","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bneo.2026.100281_bib8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/blood.V128.22.120.120","article-title":"Cereblon splicing of Exon 10 mediates IMiDs resistance in multiple myeloma: clinical validation in the CoMMpass trial","volume":"128","author":"Neri","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100281_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015909","article-title":"Loss of COP9-Signalosome genes at 2q37 is associated with IMiD agent resistance in multiple myeloma","author":"Gooding","year":"2022140161816","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100281_bib10","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.3324\/haematol.2019.217943","article-title":"IKZF1\/3 and CRL4(CRBN) E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma","volume":"105","author":"Barrio","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2026.100281_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","article-title":"ETV4-dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma","volume":"5","author":"Neri","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"22","key":"10.1016\/j.bneo.2026.100281_bib12","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.2024025861","article-title":"Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma","volume":"145","author":"Chrisochoidou","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100281_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl Variant Effect Predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100281_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100281_bib15","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1021\/acs.jproteome.2c00092","article-title":"SimPLIT: simplified sample preparation for large-scale isobaric tagging proteomics","volume":"21","author":"Sialana","year":"2022","journal-title":"J Proteome Res"},{"key":"10.1016\/j.bneo.2026.100281_bib16","article-title":"Phantasus, a web based application for visual and interactive gene expression analysis","author":"Kleverov M, Zenkova","year":"2024","journal-title":"Elife"},{"issue":"W1","key":"10.1016\/j.bneo.2026.100281_bib17","doi-asserted-by":"crossref","first-page":"W415","DOI":"10.1093\/nar\/gkae456","article-title":"WebGestalt 2024: faster gene set analysis and new support for metabolomics and multi-omics","volume":"52","author":"Elizarraras","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bneo.2026.100281_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ymben.2015.09.008","article-title":"convISA: a simple, convoluted method for isotopomer spectral analysis of fatty acids and cholesterol","volume":"32","author":"Tredwell","year":"2015","journal-title":"Metab Eng"},{"issue":"2","key":"10.1016\/j.bneo.2026.100281_bib19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100281_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13059-021-02540-7","article-title":"Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects","volume":"22","author":"Dempster","year":"2021","journal-title":"Genome Biol"},{"issue":"14","key":"10.1016\/j.bneo.2026.100281_bib21","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3682","article-title":"A CRISPR competition assay to identify cancer genetic dependencies","volume":"10","author":"Girish","year":"2020","journal-title":"Bio Protoc"},{"issue":"18","key":"10.1016\/j.bneo.2026.100281_bib22","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","article-title":"Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing","volume":"26","author":"D'Agostino","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bneo.2026.100281_bib23","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/sj.leu.2402501","article-title":"The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells","volume":"16","author":"van de Donk","year":"2002","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2026.100281_bib24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ajh.25778","article-title":"Statin use is associated with improved survival in multiple myeloma: a Swedish population-based study of 4315 patients","volume":"95","author":"Br\u00e5nvall","year":"2020","journal-title":"Am J Hematol"},{"issue":"33","key":"10.1016\/j.bneo.2026.100281_bib25","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2016.68.3482","article-title":"Statins are associated with reduced mortality in multiple myeloma","volume":"34","author":"Sanfilippo","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:51:38Z","timestamp":1790427098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950328026000920"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100281","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IMiD\/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100281"}}